A 15 Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF 06649751 in Subjects with Motor Fluctuations due to PD
Administered By
Awarded By
Contributors
- Scott, Burton Lasater Principal Investigator
Start/End
- July 1, 2016 - December 31, 2018